NCT00004482

Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (planned)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

OBJECTIVES: I. Assess the effect of immunosuppression with muromonab-CD3, cyclosporine, methylprednisolone, and prednisone versus standard care in terms of death, heart transplantation, or left ventricular assistive device placement in patients with giant cell myocarditis. II. Compare left ventricular ejection fraction prior to and after 4 weeks of treatment in these arms. III. Compare the degree of myocardial inflammatory infiltrate prior to and after 4 weeks of treatment in these arms.

Detailed description

PROTOCOL OUTLINE: This is a randomized, open label, multicenter study. Patients are randomized to receive standard care with immunosuppression (arm I) or standard care with or without immunosuppression (no muromonab-CD3 or cyclosporine)(arm II). Arm I: Patients receive methylprednisolone IV once daily for 3 days and muromonab-CD3 IV once daily for 10 days. Oral cyclosporine is administered twice daily and oral prednisone is administered once daily for 1 year. Arm II: Patients receive standard care with or without immunosuppression (no muromonab-CD3 or cyclosporine). Patients are followed for one year.

Conditions

• Myocarditis
• Giant Cell Myocarditis

Interventions

Type	Name	Description
DRUG	Cyclosporine
DRUG	methylprednisolone
DRUG	Muromonab-CD3
DRUG	prednisone

Timeline

• Start date: 1999-12-01
• Primary completion: 2005-07-01
• Completion: 2006-07-01
• First posted: 1999-10-19
• Last updated: 2010-09-09

Locations

1 site across 1 country: United States